Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. The methods for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 6 months.
With a $42.0 billion market value, Cellect Biotechnology Ltd (NULL:APOP) ranks in the top decile in its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's Portfolio Grader ranking places it 46 among the 350 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 116 among the 782 companies in the sector, and number 670 in the nearly 5,000 company Portfolio Grader universe.